Literature DB >> 1192012

e Antigen-antibody system as indicator of liver damage in patients with hepatitis-B antigen.

N El Sheikh, I L Woolf, R M Galbraith, A L Eddleston, I W Dymock, R Williams.   

Abstract

The clinical relevance of the e antigen-antibody system was investigated in 61 people persistently positive for hepatitis-B surface antigen, including 22 healthy carriers. The e antigen was not detectable in any of the healthy carriers, whereas it was found in 15 out of 28 patients with chronic aggressive hepatitis and two out of 11 with chronic persistent hepatitis. Its presence therefore indicates chronic liver disease but its absence does not exclude it. It may prove to be a particularly useful prognostic aid in chronic persistent hepatitis, since one of the two patients in whom it was found later developed aggressive hepatitis. In contrast, e antibody is of little diagnostic help, for, though it was found mostly in healthy carriers (18;82%), it was also detectable in 9 (23%) of the patients with chronic hepatitis. In 13 (76%) of the patients positive for e antigen Dane particles were seen on electron microscopy, but these were also present in 5 (19%) of the patients positive for e antibody. These findings are consistent with other evidence suggesting that e antigen is not a surface component of the Dane particle, but rather an independent soluble protein manufactured by the host in response to infection with the hepatitis-B virus.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1192012      PMCID: PMC1675054          DOI: 10.1136/bmj.4.5991.252

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

1.  Additional specificities of Australia antigen and the possible identification of hepatitis carriers.

Authors:  C Levene; B S Blumberg
Journal:  Nature       Date:  1969-01-11       Impact factor: 49.962

2.  Incidence and meaning of the "e" determinant among hepatitis-B-antigen positive patients with acute and chronic liver diseases. Report from the Copenhagen Hepatitis Acuta Programme.

Authors:  J O Nielsen; O Dietrichson; E Juhl
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

3.  New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants.

Authors:  L O Magnius; J A Espmark
Journal:  J Immunol       Date:  1972-11       Impact factor: 5.422

4.  The heterogeneity of Australia antigen.

Authors:  G L Le Bouvier
Journal:  J Infect Dis       Date:  1971-06       Impact factor: 5.226

5.  A classification of chronic hepatitis.

Authors:  J De Groote; V J Desmet; P Gedigk; G Korb; H Popper; H Poulsen; P J Scheuer; M Schmid; H Thaler; E Uehlinger
Journal:  Lancet       Date:  1968-09-14       Impact factor: 79.321

6.  Prognosis of chronic persistent hepatitis.

Authors:  M D Becker; A Baptista; P J Scheuer; S Sherlock
Journal:  Lancet       Date:  1970-01-10       Impact factor: 79.321

7.  Asymptomatic liver disease in hepatitis B antigen carriers.

Authors:  I L Woolf; B E Boyes; D M Jones; J S Whittaker; E Tapp; R N MacSween; P H Renton; F Stratton; I W Dymock
Journal:  J Clin Pathol       Date:  1974-05       Impact factor: 3.411

8.  New antigen-antibody system in Australia-antigen-positive hepatitis.

Authors:  J D Almeida; D Rubenstein; E J Stott
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

9.  Characterization of a new antigen-antibody system associated with hepatitis B.

Authors:  L O Magnius
Journal:  Clin Exp Immunol       Date:  1975-05       Impact factor: 4.330

  9 in total
  23 in total

1.  Incidence and significance of hepatitis B e antigen and antibody in postnecrotic cirrhosis and primary hepatocellular carcinoma.

Authors:  P Coursaget; P Maupas; A Goudeau; J Drucker
Journal:  J Clin Microbiol       Date:  1978-04       Impact factor: 5.948

2.  Radioimmunoassay in the detection of the hepatitis B e antigen/antibody system in asymptomatic carriers of hepatitis B surface antigen. Correlation with serum Dane particle associated DNA polymerase activity.

Authors:  G Pastore; A R Zanetti; P Ferroni; P Dentico; G Angarano; O Schiraldi
Journal:  Infection       Date:  1979       Impact factor: 3.553

3.  The significance of the HBeAg/anti-HBe system in hemodialysis patients. A multicenter study.

Authors:  F Fiaccadori; S David; G Faggion; N Feriani; C Ferrari; V Franco; T Giuberti; C Grutta D'Auria; G La Greca; G Magnani
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

4.  Correlations between the detection of e antigen or antibody and electron microscopic pattern of hepatitis B surface antigen (HBsAg) associated particles in the serum of HBsAg carriers.

Authors:  C Trepo; R G Bird; A J Zuckerman
Journal:  J Clin Pathol       Date:  1977-03       Impact factor: 3.411

5.  e Antigen and antibody in outbreaks of hepatitis B in two renal dialysis units.

Authors:  P E Gibson
Journal:  J Clin Pathol       Date:  1977-08       Impact factor: 3.411

6.  Hepatitis B e-antigen titres for evaluating infectivity during hepatitis B virus infection.

Authors:  E G Lindenschmidt; C F Granato; C Salefsky; R Laufs; H Henning
Journal:  Klin Wochenschr       Date:  1984-03-01

Review 7.  Recent advances in the identification of hepatitis viruses.

Authors:  J L Dienstag; R H Purcell
Journal:  Postgrad Med J       Date:  1977-07       Impact factor: 2.401

8.  Anti-HBc, HBeAg and DNApolymerase activity in healthy HBsAg carriers and patients with inflammatory liver diseases.

Authors:  W Arnold; G Hess; R H Purcell; P M Kaplan; J L Gerin; K H Meyer
Journal:  Klin Wochenschr       Date:  1978-03-15

9.  A study on the relationship between the prognosis of chronic active hepatitis and the HBV associated antigen/antibody systems.

Authors:  Y Kosaka; Y Tameda; Y Okuda; K Takase; H Sawa; H Takezawa
Journal:  Gastroenterol Jpn       Date:  1981-12

10.  e-Antigen: a link between immune response and infectivity in hepatitis B?

Authors:  G C Turner; H T Green; V D Blundell
Journal:  J Hyg (Lond)       Date:  1978-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.